Cargando…
Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects
Ewing sarcoma (ES) is an aggressive malignancy driven by an oncogenic fusion protein, EWS-FLI1. Neuropeptide Y (NPY), and two of its receptors, Y1R and Y5R are up-regulated by EWS-FLI1 and abundantly expressed in ES cells. Paradoxically, NPY acting via Y1R and Y5R stimulates ES cell death. Here, we...
Autores principales: | Tilan, Jason U., Lu, Congyi, Galli, Susana, Izycka-Swieszewska, Ewa, Earnest, Joshua Patrick, Shabbir, Asim, Everhart, Lindsay M., Wang, Shuo, Martin, Samantha, Horton, Meredith, Mahajan, Akanksha, Christian, David, O'Neill, Alison, Wang, Hongkun, Zhuang, Tingting, Czarnecka, Magdalena, Johnson, Michael D., Toretsky, Jeffrey A., Kitlinska, Joanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926843/ https://www.ncbi.nlm.nih.gov/pubmed/24318733 |
Ejemplares similares
-
High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases
por: Hong, Sung-Hyeok, et al.
Publicado: (2015) -
Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance
por: Czarnecka, Magdalena, et al.
Publicado: (2014) -
Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma
por: Lu, Congyi, et al.
Publicado: (2022) -
Publisher Correction: Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma
por: Lu, Congyi, et al.
Publicado: (2022) -
Neuropeptide Y and its Y2 Receptor – Potential Targets in Neuroblastoma Therapy
por: Lu, Congyi, et al.
Publicado: (2010)